WallStSmart
HALO

Halozyme Therapeutics Inc

NASDAQ: HALO · HEALTHCARE · BIOTECHNOLOGY

$63.06
-1.25% today

Updated 2026-04-29

Market cap
$7.47B
P/E ratio
24.63
P/S ratio
5.35x
EPS (TTM)
$2.56
Dividend yield
52W range
$48 – $82
Volume
1.6M

Halozyme Therapeutics Inc (HALO) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20062007200820092010201120122013201420152016201720182019202020212022202320242025
Operating cash flow$7.08M$-147660.00$-35.37M$-40.15M$-45.39M$-34.35M$-64.33M$-49.34M$-47.52M$-37.08M$-50.38M$134.05M$-49.50M$-85.42M$55.45M$299.44M$240.11M$388.57M$479.06M$651.56M
Capital expenditures$364799.00$2.37M$1.16M$1.46M$646544.00$828508.00$1.41M$2.30M$1.37M$2.36M$3.14M$1.35M$4.66M$4.04M$2.50M$1.46M$4.81M$15.29M$10.70M$6.97M
Depreciation
Stock-based comp$3.70M$4.53M$4.87M$5.57M$8.35M$9.54M$15.27M$20.84M$25.59M$30.67M$35.70M$34.78M$17.20M$20.82M$24.40M$36.62M$43.38M$51.56M
Free cash flow$6.71M$-2.51M$-36.53M$-41.61M$-46.03M$-35.18M$-65.74M$-51.64M$-48.89M$-39.44M$-53.52M$132.70M$-54.16M$-89.46M$52.95M$297.98M$235.30M$373.28M$468.37M$644.59M
Investing cash flow
Financing cash flow
Dividends paid$0.00$0.00$0.00$0.00$0.00$0.00$0.00$14.22M$63.39M$12.54M$13.48M
Share repurchases
Debt repayment
Net change in cash$-30.43M$47.08M$-72.14M$34.03M$-18.10M$23.47M$101.98M$-110.80M$62.24M$27.52M$-28.98M$115.48M